Q-omics provides the consensus-scored TMEM71 profile across patient tissues and cancer cell-line models. TMEM71 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TMEM71 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, TMEM71 RNA expression shows 16,703 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KICH, and LSCC as cancer lineages where TMEM71 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM71 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM71 survival associations across molecular data types. TMEM71 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM71 RNA expression–survival associations across cancer types. High TMEM71 expression shows unfavorable associations in LGG and ACC, but favorable associations in HNSC, UCEC, BRCA and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TMEM71 RNA expression.
This table summarizes TMEM71 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM71. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM71 shows lower tumor expression in KICH, BRCA, LUSC, UCEC and HNSC and higher tumor expression in KIRC. The KICH box plot shows higher TMEM71 RNA expression in normal versus tumor tissue (log2 FC = −1.234, t-test p < 0.001).
This table shows molecular features associated with TMEM71 in patient tissues and cancer cell lines. In patient samples, TMEM71 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM71 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
